BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

by Ysios Capital

BioClin Therapeutics, Inc., a privately-­‐held clinical stage drug development company developing a first-­‐in-­‐class anti-­‐FGFR3 (fibroblast growth factor receptor 3) monoclonal antibod...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Regenera Levante partners with Magnum Ca...

by Magnum Capital Partners

Over little more than a decade, Regenera has built a strong track reco...

Photos Stream